Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Knopp raises $10 million in series B funding
The latest financing involved the exercise of milestone-based callable warrants held by existing investors in Knopp. The company anticipates making a further series B call of $10 million
The latest financing involved the exercise of milestone-based callable warrants held by existing investors in Knopp. The company anticipates making a further series B call of $10 million
The company was informed that this decision was based on the need for additional analysis from previously completed animal toxicology studies with arimoclomol. Arimoclomol has been shown to
Lumar Diagnostic Imaging will operate as a wholly-owned subsidiary of Bederra when the acquisition is completed by the end of the first quarter 2008. Graham Williams, president of
AstraZeneca’s Phase II program will consist of two separate studies in patients with severe sepsis. The first study, which is now underway, is designed to assess the safety,
The Everest trial was designed to determine whether cortical stimulation in conjunction with rehabilitation therapy would lead to greater gains in hand and arm function and activities of
The Phase III clinical trial results on which this approval was based demonstrated that Abraxane doubled the response rate and significantly prolonged progression-free survival and overall survival versus
The Biosafe diabetes risk assessment is a two-part process comprised of an immediate fasting glucose reading and a mail-in laboratory analysis for hemoglobin A1c, a blood glucose marker
Lyophilized syringin powder for injection is developed independently by Renhuang as a new form of pure Chinese herbal medicine that does not have any of the side-effects of
Fast track status indicates that the FDA has recognized that Sabril is intended for the treatment of a serious or life-threatening condition for which there are no available
This Phase IB trial is focused on finding the optimal dosage for the formulation of Oramed’s proprietary oral insulin delivery technology. The study utilizes healthy human volunteers in